Evotec AG: LAB282 Accelerates with Second Round Funding


LAB 282 is providing critical early stage guidance and industry validation to novel therapeutic concepts. LAB 282 's steering committee decided to support five of those concepts with significant awards: Combined with financial support the five projects will receive ongoing translational support from Oxford University Innovation , the University's research commercialisation company, and full access to Evotec's pre-clinical platforms and expertise.



from Biotech News